Dr. Prism Schneider, MD
Claim this profileFoothills Medical Centre
Affiliated Hospitals
Foothills Medical Centre
University Of Calgary
Clinical Trials Prism Schneider, MD is currently running
Oral Blood Thinners
for Hip Fracture
As our Canadian population ages, hip fractures in these older adults are becoming very common. The best treatment for the majority of these injuries is urgent treatment with surgery. However, the hip fracture itself, the surgery required, and the immobility following these injuries are all risk factors for developing blood clots in the legs (deep vein thrombosis or DVT) and blood clots in the lungs (pulmonary embolism or PE). These complications are a common cause of death in patients with hip fractures and often result in prolonged medical treatment and hospital stays. Patients with hip fractures who require surgery are traditionally given injectable blood thinners to help prevent blood clots; however, these medications are costly, may not be tolerated well, and can be difficult to take, as prescribed. Oral blood thinning medications are being used more commonly, but it is unknown which of these medications is the most effective in preventing blood clots in patients after a hip fracture. Thrombelastography (TEG) technology uses a small sample of blood to evaluate a person's clotting ability. Our research has used TEG technology to evaluate blood clotting risk after hip fracture surgery and the investigators have found that platelets may play an important role in abnormal blood clotting after a hip fracture. The investigators have also shown that acetylsalicylic acid (ASA or Aspirin) may help reduce the abnormal platelet hyperactivity associated with blood clotting. This medication warrants investigation for blood clot prevention after hip fracture. The investigators propose to directly compare different oral medication regimens after hip fracture surgery, in order to determine which is safest and most effective in preventing blood clots. Our multi-disciplinary research team includes physicians, surgeons, and scientists with experience evaluating different medications for blood clot prevention. Our results will help determine the best medical treatment for preventing DVT and PE, which will benefit patients with hip fractures worldwide.
Recruiting
1 award
Phase 2
FitJoints Program
for Hip and Knee Osteoarthritis
Total hip or knee replacement is an important and cost-effective surgical intervention to relieve pain and improve independence and function in patients with osteoarthritis. The number of people waiting for elective surgeries has spiked in the COVID-19 pandemic. Prior to COVID-19, up to 40% of patients receiving joint replacement were frail and this number is rapidly increasing with longer wait-times and deconditioning associated with COVID-19 physical distancing. There is an urgent need to be responsive to the evolving challenges of healthcare. The proposed study is the first multi-site randomized controlled trial (RCT) to examine whether a multimodal frailty reduction intervention before surgery will improve postsurgical outcomes for this population. The COVID-19 adapted hybrid model includes a multimodal frailty intervention that may be implemented either in person or virtually and is aligned with international consensus guidelines on frailty reduction. To utilize the FitJoints multimodal frailty intervention to build resilience of patients undergoing joint replacement surgery to improve post-operative outcomes. The investigators hypothesize the FitJoints multimodal frailty intervention, with exercise, nutrition and medication optimization, will reduce frailty and pain while improving function and quality of life. Building upon the success of the FitJoints feasibility study (n=69) in Hamilton, Ontario, in the proposed multi-site RCT (n=192), older adults (≥60 years) undergoing hip or knee joint replacement surgery who are frail will be randomized to either the 3 to 6-months of multimodal intervention or usual care until the date of their surgery at multiple sites (Hamilton Health Sciences \& St Joseph's Healthcare Hamilton, ON; London Health Science Centre, London, ON; Foothills Hospital, Calgary, AB),The FitJoints evidence-based, multimodal intervention includes a hybrid model that can be implemented either in person or virtually: 1. Physiotherapist supported multi-component exercise program 2. Nutrition and protein optimization including dietary counseling 3. Medication review with prescribing recommendations
Recruiting
1 award
N/A
More about Prism Schneider, MD
Clinical Trial Related
6 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Prism Schneider, MD has experience with
- Acetylsalicylic Acid (ASA) 81mg Oral Tablet
- Rivaroxaban 10mg
- Hardware Removal
- Cognitive Behavioural Therapy
- Implant Removal
- Lactose Placebo
Breakdown of trials Prism Schneider, MD has run
Osteoarthritis
Subtrochanteric Fracture
Hip Fracture
Tarsometatarsal Joint Fracture Dislocation
Tarsometatarsal Joint Dislocation/Fracture
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Prism Schneider, MD specialize in?
Prism Schneider, MD focuses on Osteoarthritis and Subtrochanteric Fracture. In particular, much of their work with Osteoarthritis has involved treating patients, or patients who are undergoing treatment.
Is Prism Schneider, MD currently recruiting for clinical trials?
Yes, Prism Schneider, MD is currently recruiting for 2 clinical trials in Calgary Alberta. If you're interested in participating, you should apply.
Are there any treatments that Prism Schneider, MD has studied deeply?
Yes, Prism Schneider, MD has studied treatments such as Acetylsalicylic acid (ASA) 81mg Oral Tablet, Rivaroxaban 10mg, Hardware removal.
What is the best way to schedule an appointment with Prism Schneider, MD?
Apply for one of the trials that Prism Schneider, MD is conducting.
What is the office address of Prism Schneider, MD?
The office of Prism Schneider, MD is located at: Foothills Medical Centre, Calgary, Alberta T2N 5A1 Canada. This is the address for their practice at the Foothills Medical Centre.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.